Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
Top Cited Papers
- 1 February 2008
- journal article
- research article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 145 (2) , 239-248.e5
- https://doi.org/10.1016/j.ajo.2007.10.004
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Tolerability and Efficacy of Multiple Escalating Doses of Ranibizumab (Lucentis) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Ranibizumab for Treatment of Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfinOphthalmology, 2001
- Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With VerteporfinArchives of Ophthalmology (1950), 1999
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988